Economic information and modeling report
Modeling overview
23 evidence topics · 16 sources
Summary: ICER assessment, other published economic evaluations, and commercial forecasts
The Institute for Clinical and Economic Review (ICER) assessed baxdrostat and lorundrostat for hypertension in a 2026 evidence report discussed at the “Midwest CEPAC 2026 public meeting on aldosterone synthase inhibitors for hypertension”. The assessment page lists a “Final Evidence Report and Meeting Summary”, and ICER's meeting slides state that the final report would be published “on or around November 30, 2026”. ICER rated the evidence for lorundrostat or baxdrostat compared with spironolactone, eplerenone, or amiloride as “Promising but Inconclusive” in participants with resistant hypertension or intolerance of a third first-line drug (Populations 1 and 2), as “comparable or inferior” to amlodipine in participants not yet treated with a third drug (Population 3), and as insufficient to distinguish lorundrostat from baxdrostat. ICER's lifetime model used the 50 mg once-daily dose of lorundrostat and a placeholder price equal to the baxdrostat wholesale acquisition cost ($10,950 per year). At that price, lorundrostat cost $1,419,000 per QALY gained compared with spironolactone and $1,492,000 compared with amiloride, and was “More costly, less effective” than eplerenone, which ICER attributed to a 10% first-cycle discontinuation probability for lorundrostat against 7.7% for eplerenone. Lorundrostat was cost-effective in 0.0% of probabilistic simulations at $150,000 per evLY gained, and the health-benefit price benchmark for lorundrostat was $760 to $1,600 per year (85.7% to 93.0% below the placeholder price), against $1,400 to $2,500 per year for baxdrostat. Mineralys commented that the model “does not fully capture the clinical and economic benefits of ASIs”, that first-cycle discontinuation of lorundrostat (10%) was based on Launch-HTN and that of eplerenone and amiloride (7.7%) on a study of Swedish patients receiving calcium channel blockers, and that models should incorporate dynamic pricing; a commenting coalition, No Patient Left Behind, estimated a societal value-based price of $18,767 to $26,913 per year. A 2026 review states that cost-effectiveness evidence for aldosterone synthase inhibitors is still needed. No published cost-effectiveness analysis of spironolactone, eplerenone, amiloride, or aprocitentan for resistant hypertension was identified; a 2026 systematic review found 21 modelling studies in treatment-resistant and uncontrolled hypertension, 12 of 14 cost-utility analyses evaluating renal denervation. Published analyses report $32,732 per QALY for radiofrequency renal denervation (Medicare payer perspective), $12,900 per QALY for ultrasound renal denervation, $3,071 per QALY in a 2012 societal-perspective model in resistant hypertension, $4,400 per QALY for team-based care with non-physician titration, and cost savings of $10,162 per person for pharmacist prescribing. No sales forecast from Mineralys was identified; GlobalData forecast lorundrostat sales of $601 million in 2030, and Visible Alpha consensus projected risk-adjusted sales of $122 million in 2027 and $365 million in 2028, with analysts expecting annual revenue of $1.1 billion by 2030.
ICER evidence ratings
ICER cost-effectiveness model: structure, perspective, and populations
ICER cost-effectiveness model: treatment effect inputs
| Parameter | Quoted input |
|---|---|
| SBP reduction for lorundrostat vs. placebo (mm Hg) | “9.0, (95% CrI: 1.7, 16.4)” |
| SBP reduction for baxdrostat vs. placebo (mm Hg) | “11.0 (95% CrI: 7.3, 14.6)” |
| SBP reduction for spironolactone vs. placebo (mm Hg) | “10.1 (95% CrI: 6.7, 13.1)” |
| SBP reduction for eplerenone vs. placebo (mm Hg) | “8.8 (95% CrI: 2.3, 15.5)” |
| SBP reduction for amiloride vs. placebo (mm Hg) | “6.6 (95% CrI: 1.4, 11.6)” |
| Hazard ratio for stroke, per 5 mm Hg SBP reduction | “0.87 (95% CI: 0.84, 0.91)” |
| Hazard ratio for ischemic heart disease, per 5 mm Hg SBP reduction | “0.92 (95% CI: 0.89, 0.95)” |
| Hazard ratio for heart failure, per 5 mm Hg SBP reduction | “0.87 (95% CI: 0.83, 0.92)” |
| Relative risk for ESKD, per 10 mm Hg SBP reduction | “0.95 (95% CI: 0.84, 1.07)” |
ICER cost-effectiveness model: base-case results at the placeholder price
| Treatment | Intervention acquisition costs | Non-intervention costs | Total costs | QALYs | evLYs | LYs |
|---|---|---|---|---|---|---|
| Lorundrostat (placeholder price) | “$28,500” | “$122,200” | “$150,700” | “9.54” | “9.54” | “11.86” |
| Baxdrostat | “$27,600” | “$122,000” | “$149,600” | “9.55” | “9.55” | “11.87” |
| Spironolactone | “$200” | “$122,600” | “$122,800” | “9.52” | “9.52” | “11.83” |
| Eplerenone | “$2,000” | “$122,200” | “$124,300” | “9.54” | “9.54” | “11.86” |
| Amiloride | “$830” | “$122,500” | “$123,400” | “9.52” | “9.52” | “11.84” |
| Treatment and comparator | Cost per QALY gained | Cost per evLY gained | Cost per life year gained |
|---|---|---|---|
| Lorundrostat (placeholder price) vs. spironolactone | “$1,419,000” | “$1,327,000” | “$1,213,000” |
| Lorundrostat (placeholder price) vs. eplerenone | “More costly, less effective” | “More costly, less effective” | “More costly, less effective” |
| Lorundrostat (placeholder price) vs. amiloride | “$1,492,000” | “$1,403,000” | “$1,273,000” |
| Baxdrostat vs. spironolactone | “$833,000” | “$781,000” | “$712,000” |
| Baxdrostat vs. eplerenone | “$2,077,000” | “$1,954,000” | “$1,774,000” |
| Baxdrostat vs. amiloride | “$851,000” | “$800,000” | “$727,000” |
ICER cost-effectiveness model: sensitivity and probabilistic analyses
| Lorundrostat (placeholder price) compared with | Cost-effective at $50,000 per evLY gained | Cost-effective at $100,000 per evLY gained | Cost-effective at $150,000 per evLY gained | Cost-effective at $200,000 per evLY gained |
|---|---|---|---|---|
| Spironolactone | “0.0%” | “0.0%” | “0.0%” | “0.0%” |
| Eplerenone | “0.0%” | “0.0%” | “0.0%” | “0.2%” |
| Amiloride | “0.0%” | “0.0%” | “0.0%” | “0.2%” |
ICER cost-effectiveness model: scenario analyses
| Scenario (cost per QALY gained, lorundrostat at the placeholder price) | Compared with spironolactone | Compared with eplerenone | Compared with amiloride |
|---|---|---|---|
| Modified societal perspective | “$1,404,000” | “Lower effect, higher cost” | “$1,479,000” |
| Same discontinuation for all treatments | “$1,322,000” | “$16,455,000” | “$1,382,000” |
| No discontinuation for all treatments | “Lower effect, higher cost” | “$16,956,000” | “$1,436,000” |
| 10-year treatment effect duration | “$1,698,000” | “Lower effect, higher cost” | “$1,577,000” |
| 20-year treatment effect duration | “$1,437,000” | “Lower effect, higher cost” | “$1,498,000” |
| 5-year time horizon | “$28,854,000” | “$166,418,000” | “$10,593,000” |
| 10-year time horizon | “$5,392,000” | “$123,253,000” | “$3,622,000” |
| Minimum price for generic comparators | “$1,428,000” | “Lower effect, higher cost” | “$1,521,000” |
ICER health-benefit price benchmark and threshold prices
| Intervention and outcome measure | Annual WAC | Annual price at $100,000 threshold | Annual price at $150,000 threshold | Discount from WAC to reach threshold prices |
|---|---|---|---|---|
| Lorundrostat, QALYs gained (placeholder price) | “$10,950” | “$760” | “$1,500” | “86.3% - 93.0%” |
| Lorundrostat, evLYs gained (placeholder price) | “$10,950” | “$770” | “$1,600” | “85.7% - 93.0%” |
| Baxdrostat, QALYs gained | “$10,950” | “$1,400” | “$2,400” | “78.3% - 87.4%” |
| Baxdrostat, evLYs gained | “$10,950” | “$1,400” | “$2,500” | “77.2% - 87.1%” |
| Lorundrostat compared with (QALY-based) | Annual price to achieve $50,000 per QALY gained | Annual price to achieve $100,000 per QALY gained | Annual price to achieve $150,000 per QALY gained | Annual price to achieve $200,000 per QALY gained |
|---|---|---|---|---|
| Spironolactone | “$600” | “$980” | “$1,400” | “$1,700” |
| Eplerenone | “$770” | “$770” | “$760” | “$760” |
| Amiloride | “$790” | “$1,100” | “$1,500” | “$1,900” |
ICER cost-effectiveness model: limitations and conclusion
ICER comparison with prior economic models
Manufacturer comments on the ICER draft evidence report
ICER responses to the manufacturer comments
Stakeholder exploratory analyses of dynamic pricing and societal value
Published cost-effectiveness analyses of lorundrostat other than the ICER assessment
No evidence found.
Cost-effectiveness evidence needed for aldosterone synthase inhibitors
“The ASIs represent a promising class of antihypertensive drug classes with proven efficacy in reducing both office and ambulatory blood pressure, although studies on their comparative efficacy and safety with MRAs such as spironolactone are needed, along with evidence of cost-effectiveness.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Published cost-effectiveness analyses of spironolactone, eplerenone, amiloride, or aprocitentan for resistant hypertension
No evidence found.
Systematic review of economic models in treatment-resistant and uncontrolled hypertension
“A total of 21 modelling studies were included: 16 economic evaluations (14 cost-utility analyses, 1 cost-effectiveness analysis and 1 cost-minimization analysis), 4 burden-of-illness studies and 1 budget impact analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 14 CUAs, 12 evaluated RDN: of these, 7 evaluations comparing radio frequency (RF) RDN plus standard of care (SoC) to SoC alone in different healthcare settings were based on the same model” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although models were generally assessed to be of good quality, models incorporated health-related quality of life and cost data from controlled hypertensive or non-hypertensive populations, rather than those with ucHTN and trHTN.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Radiofrequency renal denervation, United States Medicare payer perspective
“A decision-analytic Markov model projected costs, quality-adjusted life years (QALY), and clinical events for an active cohort treated with RF RDN and a control cohort treated with standard-of-care (defined as 1, 2, or 3 antihypertensive medications).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The model projected costs and effects with a lifetime horizon from a Medicare payer perspective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over lifetime, RF RDN added 0.34 QALY at an additional cost of $11,275, leading to an incremental cost-effectiveness ratio of $32,732 per QALY.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ultrasound renal denervation, United States health care system perspective
“A previously published Markov model was adapted to compare total costs and quality-adjusted life years (QALY) between uRDN plus standard of care (SoC) vs SoC alone over a lifetime horizon from a US health care system perspective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Using a procedure cost of $23,000, total lifetime costs were higher with the uRDN procedure (uRDN plus SoC: $110,476 vs SoC alone: $102,875), resulting in an incremental cost-effectiveness ratio of $12,900 per QALY.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Catheter-based renal denervation for resistant hypertension, first United States model
“We adopted a societal perspective and estimated an incremental cost-effectiveness ratio in U.S. dollars per quality-adjusted life-year, both discounted at 3% per year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The discounted lifetime incremental cost-effectiveness ratio was $3,071 per quality-adjusted life-year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Team-based care with non-physician medication titration, United States
“Relative to usual care at 10 years, TBC with non-physician titration was estimated to cost $95 (95% uncertainty interval: -$563 to $664) more per patient and gain 0.022 (0.003 to 0.042) QALYs, costing $4,400/QALY gained.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacist prescribing for hypertension, United States
“The intervention was also associated with 0.34 (2.5th-97.5th percentiles, 0.23-0.45) additional life years and 0.62 (2.5th-97.5th percentiles, 0.53-0.73) additional QALYs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The cost savings were $10 162 (2.5th-97.5th percentiles, $6636-$13 581) per person due to fewer CV events with the pharmacist-prescribing intervention, even after the cost of the visits and medication adjustments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote